Eyenovia (NASDAQ:EYEN – Get Free Report) is expected to post its quarterly earnings results before the market opens on Monday, March 17th. Analysts expect Eyenovia to post earnings of ($8.00) per share and revenue of $1.60 million for the quarter.
Eyenovia Stock Performance
NASDAQ:EYEN opened at $1.65 on Friday. Eyenovia has a twelve month low of $1.43 and a twelve month high of $131.14. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.58. The company has a 50-day moving average of $3.50 and a 200-day moving average of $19.26. The firm has a market cap of $2.30 million, a price-to-earnings ratio of -0.03 and a beta of 1.29.
Analyst Upgrades and Downgrades
Several equities analysts have recently weighed in on the stock. HC Wainwright restated a “neutral” rating and set a $2.00 price objective on shares of Eyenovia in a research report on Thursday, February 6th. LADENBURG THALM/SH SH reaffirmed a “neutral” rating on shares of Eyenovia in a research note on Monday, November 18th.
About Eyenovia
Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.
Featured Stories
- Five stocks we like better than Eyenovia
- The 3 Best Retail Stocks to Shop for in August
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- How Investors Can Find the Best Cheap Dividend Stocks
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- The How And Why of Investing in Oil Stocks
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.